WEBULL
WebtradeDownload

Protagonist Therapeutics (PTGX) Could Be 21% Undervalued As Royalty Funded Narrative Builds

Simply Wall St · 2d ago

Protagonist Therapeutics (PTGX) drew fresh attention after its shares closed at US$138.49 on 9 October 2026. Recent trading has been mixed, with the price down over the past month but higher over the past 3 months.

Despite that softer recent stretch, momentum for Protagonist Therapeutics still leans positive, with the share price up 58.9% year to date and a 1 year total shareholder return of 80.0%. The 3 year total shareholder return of roughly 8x highlights how strongly long term holders have been rewarded.

Scan beyond Protagonist Therapeutics and size up other high-momentum biotech stories with the 20 high quality undiscovered gems that screens for smaller companies already putting solid fundamentals to work.

After that kind of run, Protagonist Therapeutics now trades well below both analyst targets and one intrinsic value estimate. Is the current US$138.49 price already generous, or still lagging fair value?

Most Popular Narrative: 21% Undervalued

The most followed narrative puts fair value for Protagonist Therapeutics at $174.69, which sits well above the recent $138.49 close. That gap reflects a view that the current quote gives limited credit to the broader royalty funded pipeline and cash position.

The transition to a royalty and milestone funded model, with around US$850 million in cash and no anticipated equity based financings in the foreseeable future, gives Protagonist Therapeutics room to advance its pipeline and run a US$300 million share repurchase program, which can influence per share earnings metrics even if total profit is unchanged.

See why 2 investors see Protagonist Therapeutics as 21% undervalued.

Result: Fair Value of $174.69 (UNDERVALUED)

Still, the bullish Protagonist Therapeutics narrative hinges on analyst forecasts. Slower royalty receipts or a lower future P/E multiple could quickly challenge that 21% undervalued story.

Find out about the key risks to this Protagonist Therapeutics narrative.

Another View: Protagonist Therapeutics Through The P/E Lens

The DCF work paints Protagonist Therapeutics as deeply undervalued, with the current US$138.49 price sitting 75.1% below one fair value estimate of US$557. On a plain P/E ratio though, the stock looks demanding at 108.1x, compared with 67.7x for peers and a fair ratio of 27.8x. That gap raises a simple question for you as an investor: Is the risk of the market moving closer to that lower fair ratio acceptable for your approach?

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGM:PTGX P/E Ratio as at Oct 2026
NasdaqGM:PTGX P/E Ratio as at Oct 2026

Next Steps

Sentiment around Protagonist Therapeutics is clearly upbeat, so move quickly, review the full data set, and decide whether that optimism fits your own approach through the 4 key rewards.

Looking for more Protagonist Therapeutics sized opportunities?

If Protagonist Therapeutics has your attention, do not stop with a single ticker. Use the Simply Wall St screener to surface fresh, data driven ideas that match your style.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.